AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04280367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standardised semi-structured talk
Description: Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Study NCT04280367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autistic spectre disorder screening
Description: Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Study NCT02704156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberknife plus Pembrolizumab and Trametinib
Description: Radiation therapy plus drug
Study NCT02704156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cyberknife plus Gemcitabine
Description: Radiation therapy plus drug
Study NCT00605605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 120 mg/day, single once daily dose taken after breakfast by oral route
Study NCT03009123 — intervention group
Intervention type: OTHER
Intervention: Erectile dysfunction
Description: Patients with ED are considered belonging to the exposure group.
Study NCT04280367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety measuring
Description: An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Study NCT05209022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 140 mL of beetroot juice or beetroot juice placebo
Study NCT05209022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice
Description: 140 mL of beetroot juice or beetroot juice placebo
Study NCT00620438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine-artemether and nevirapine
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
Study NCT00620438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumefantrine-artemether and efavirenz
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
Study NCT00620438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumefantrine-artemether and rifampicin
Description: Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
Study NCT03023033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth messaging
Description: SMS appointment reminders and health messaging via mobile phones
Study NCT03023033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transport Payments
Description: A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
Study NCT01499251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Dose Escalation
Description: Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Study NCT02240615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys Lacrimal Stent
Description: Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
Study NCT04110210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided Erector Spinae Plane Block
Description: Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
Study NCT04110210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Consumption
Description: After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug Counseling (DC)
Description: The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Counseling (DC)
Description: The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management (CM)
Description: The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
Study NCT02896712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
Study NCT01499251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1b
Description: Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
Study NCT01499251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancillary Study
Description: Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Study NCT02896712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo capsule will be filled with corn starch and riboflavin.
Study NCT02896712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
Study NCT01379157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
Study NCT01379157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
Study NCT01113879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
Study NCT01113879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
Study NCT01988116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Calcitriol 0.5 mcg once daily for 6 weeks
Study NCT01988116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03385252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Eggs provided as complementary food for the infant
Study NCT03385252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visits
Description: Twice weekly household visits by study staff
Study NCT03385252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visits
Description: Twice weekly household visits by study staff
Study NCT00891137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human myeloid progenitor cells
Description: Single intravenous injection/infusion
Study NCT02941835 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: pre-operative irradiation
Description: pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
Study NCT03573830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transport Canada material
Description: The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
Study NCT03573830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced material
Description: Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
Study NCT01499888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Non-Myeloablative Stem Cell Transplantation
Description: Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion
Study NCT01499888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
Study NCT01499888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
Study NCT01321775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Description: Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)
Study NCT02753699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Intervention of interest; follow-up after ALV-active study
Study NCT02051530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan depletion
Description: tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
Study NCT02408016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02097316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JewelPump
Study NCT02097316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JewelPump
Study NCT03214809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound protocol
Description: after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
Study NCT02418858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation surgery
Description: Deep Brain Stimulation surgery awake vs. asleep
Study NCT05492669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride, Injectable
Description: In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
Study NCT05492669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Study NCT02408016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT02847364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
Study NCT02730234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JetStream XC with balloon angioplasty
Description: JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
Study NCT00989417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACTIVATION of HOME MONITORING
Description: Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study NCT00989417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVATION of HOME MONITORING
Description: Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
Study NCT01577446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac resynchronization therapy
Description: Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
Study NCT00237146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT02104232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THPP-I
Study NCT02104232 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EUC
Study NCT02104232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EUC
Study NCT00529594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (Control Group)
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Study NCT00529594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib (Treatment Group)
Description: Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
Study NCT04047264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Undergo microdialysis
Study NCT04104009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study.
Study NCT04104009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No education
Description: In the control group there will be no education, no breathing exercises and no listening to classical music.
Study NCT03480997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate and Ipratropium Bromide
Study NCT03480997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Study NCT03480997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Study NCT01538862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulating Factor (GCSF)
Description: G-CSF 10mcg/kg/d SQ for 7 days
Study NCT02282956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,75%
Description: Ropivacaine injection
Study NCT02282956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior tibial nerve block
Description: ultrasound guided posterior tibal nerve block
Study NCT02720627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cortexolone 17α-propionate
Description: CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.